Theyre a common side effect of GLP-1s, as well as other injectable medications like insulin
Nadolsky sees room for smaller companies to differentiate, even with the bar set extraordinarily high
As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]
Plasma insulin response to oral and intravenous glucose administration
The third-party labs that produce these reports are often the vendors themselves and offer assurances of 98 per cent purity, which might seem impressive but would not meet any reasonable drug standards